The daily business briefing: November 10, 2020
The Dow jumps after Pfizer's vaccine news, McDonald's announces plan to roll out "McPlant" burger, and more
1. Pfizer coronavirus vaccine news sends stocks soaring
The Dow Jones Industrial Average and S&P 500 soared on Monday after drug makers Pfizer and BioNTech announced that their COVID-19 vaccine candidate was more than 90 percent effective in tests. The Dow rose by nearly 3 percent, gaining 835 points in its biggest jump since June 5 and touching an all-time intraday high. The S&P 500 gained 1.2 percent. Airlines and other travel-related stocks that have suffered heavy losses during the pandemic led the gains. The tech-heavy Nasdaq fell by 1.5 percent as many technology stocks fell after outperforming the broader market as people have done more work, learning, and shopping online during the pandemic. CNBC's Mad Money host Jim Cramer said "the rally is justifiable," and marks a beginning of a discussion about what America is "going to look like post-COVID." Dow futures rose further early Tuesday, but S&P 500 and Nasdaq futures fell.
2. McDonald's unveils plans for 'McPlant' burger
McDonald's on Monday announced that it will add a plant-based burger and other items to menus in select markets. The company said it would be testing its own "McPlant" items starting next year. The announcement came after the burger chain conducted a pilot program in Canada earlier this year selling plant-based patties mimicking meat that were made by industry leader Beyond Meat. The plant-based food company helped McDonald's develop a patty for the McPlant line, which also could include plant-based substitutes for chicken and breakfast meats. Beyond Meat shares rose on news of the collaboration, then plunged in overnight trading after the company reported earnings that fell far short of expectations due to the coronavirus crisis.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The Wall Street Journal TechCrunch
3. EU imposes tariffs on $4 billion worth of U.S. goods
The European Union on Monday outlined plans to impose tariffs on up to $4 billion worth of U.S. goods in retaliation for Trump administration levies on European products. Boeing aircraft will face a 15 percent tariff, while a variety of products, including tractors, gin, video game consoles, cotton, and salmon, will be covered by a 25 percent levy. The decision was part of an ongoing dispute over subsidies to aircraft makers. The U.S. imposed tariffs on billions of dollars worth of European goods, arguing that Europe gives unfair support to Boeing's European rival, Airbus. The EU says the U.S. gives Boeing illegal state aid. Boeing called the EU decision "disappointing."
4. Amazon expected to face anti-competition allegations in Europe
European regulators are expected Tuesday to file formal charges against Amazon accusing the online retail giant of unfair business practices, The Wall Street Journal reported, citing a person familiar with the matter. European Commission antitrust authorities have been investigating Amazon since June 2019, examining how the company gathers data from buyers and sellers and uses the information to market its own products. Regulators are expected to rule next year on whether Amazon violated competition laws. Violations are punishable with fines of up to 10 percent of global revenue, or as much as $28 billion based on Amazon's 2019 earnings. The commission also can demand that Amazon change some of its business practices, although the company can challenge any decision in court.
5. FDA approves emergency use of Eli Lilly antibody drug
The Food and Drug Administration on Monday granted emergency-use authorization for drug maker Eli Lilly's experimental antibody drug for some COVID-19 patients. The drug, bamlanivimab, is the first antibody drug to receive such approval. Doctors will be allowed to administer it to patients who are not hospitalized but who face a risk of serious illness due to their age or other conditions. Trial data showed that a one-time infusion of the drug reduced the need for hospitalization or emergency room visits for these high-risk patients. President Trump received a similar treatment, developed by Regeneron Pharmaceuticals, when he was diagnosed with COVID-19 in early October. Dr. Anthony Fauci, the nation's top infectious disease expert, said the treatment likely contributed to Trump's recovery.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Harold Maass is a contributing editor at The Week. He has been writing for The Week since the 2001 debut of the U.S. print edition and served as editor of TheWeek.com when it launched in 2008. Harold started his career as a newspaper reporter in South Florida and Haiti. He has previously worked for a variety of news outlets, including The Miami Herald, ABC News and Fox News, and for several years wrote a daily roundup of financial news for The Week and Yahoo Finance.
-
7 restaurants that beat winter at its own chilly game
The Week Recommends Classic, new and certain to feed you well
By Scott Hocker, The Week US Published
-
Crossword: December 24, 2024
The Week's daily crossword
By The Week Staff Published
-
Sudoku medium: December 24, 2024
The Week's daily medium sudoku puzzle
By The Week Staff Published
-
Why Assad fell so fast
The Explainer The newly liberated Syria is in an incredibly precarious position, but it's too soon to succumb to defeatist gloom
By The Week UK Published
-
Romania's election rerun
The Explainer Shock result of presidential election has been annulled following allegations of Russian interference
By Sorcha Bradley, The Week UK Published
-
Russia's shadow war in Europe
Talking Point Steering clear of open conflict, Moscow is slowly ratcheting up the pressure on Nato rivals to see what it can get away with.
By The Week UK Published
-
Cutting cables: the war being waged under the sea
In the Spotlight Two undersea cables were cut in the Baltic sea, sparking concern for the global network
By The Week UK Published
-
The nuclear threat: is Vladimir Putin bluffing?
Talking Point Kremlin's newest ballistic missile has some worried for Nato nations
By The Week UK Published
-
Russia vows retaliation for Ukrainian missile strikes
Speed Read Ukraine's forces have been using U.S.-supplied, long-range ATCMS missiles to hit Russia
By Arion McNicoll, The Week UK Published
-
Has the Taliban banned women from speaking?
Today's Big Question 'Rambling' message about 'bizarre' restriction joins series of recent decrees that amount to silencing of Afghanistan's women
By Harriet Marsden, The Week UK Published
-
Cuba's energy crisis
The Explainer Already beset by a host of issues, the island nation is struggling with nationwide blackouts
By Rebekah Evans, The Week UK Published